黑粉头头
Lv34
334 积分
2021-07-28 加入
-
Faricimab Treat-and-Extend for Diabetic Macular Edema
1天前
已完结
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
1天前
已完结
-
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid
2天前
已完结
-
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
2天前
已完结
-
KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema
2天前
已完结
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
3天前
已完结
-
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
3天前
已完结
-
The pathogenesis of IgA nephropathy and implications for treatment
5天前
已完结
-
IgA Nephropathy
5天前
已关闭
-
Charge and size of mesangial IgA in IgA nephropathy
5天前
已完结